Do I Really Need To File? HSR Avoidance and the Edwards/Genesis Settlement
August 24, 2026
For nearly 50 years, the Hart-Scott-Rodino Act has given antitrust enforcers a chance to review deals above a certain value before they can close. What happens when the government concludes a transaction was structured intentionally to slip past that review entirely?
Managing partner Jeny Maier and Lexi Michaud of Fried Frank speak with Evan Miller of Vinson & Elkins about HSR Act avoidance and the FTC’s record-setting $12 million settlement with Edwards Lifesciences and Genesis MedTech over Edwards Lifesciences’s acquisition of JC Medical from Genesis. They discuss how the JC Medical deal was valued and structured, how the parties' failure to file played a role in the FTC’s separate challenge to Edwards’s contemporaneous JenaValve acquisition, what deal teams should consider when assessing a transaction close to the HSR threshold, what the settlement signals about the FTC’s current approach to premerger notification enforcement, and more.
Watch below or on the Our Curious Amalgam website.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
LCA 2026 Renaissance Symposium XX
Speaking Engagement
Antitrust
Concurrences New Frontiers of Antitrust Conference 2026
Sponsorship
Antitrust
Stakeholders 26th Annual CYOC Conference
Event
Antitrust
Hot Topics in Health Care Antitrust
Podcast
Antitrust
Jimmy Attridge Repeats Recognition on Washingtonian Magazine’s 2026 Top Lawyers List
Awards & Recognitions
Antitrust
AIC General Counsel Day 2026
Speaking Engagement
Antitrust
ALFDP 20th Anniversary Annual Conference
Event
Antitrust
Antitrust After the Midterms: Planning for a Blue Wave of Congressional Investigations
Axinn Viewpoints
Antitrust
GCR Live: Women in Antitrust 2026
Sponsorship
Antitrust
GICLI Annual Meeting 2026
Sponsorship
Antitrust
